Narcolepsy Without Cataplexy
12
1
1
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
50%
4 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (12)
Decreasing Nightmares in Adults With Narcolepsy
Clarithromycin Mechanisms in Hypersomnia Syndromes
Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Awareness and Self-Compassion Enhancing Narcolepsy Treatment
Narcolepsy Nightmare Study
Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia
An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy
'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy'
Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy
A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2
Flumazenil for the Treatment of Primary Hypersomnia